The Appellate Division, offering some guidance on the “alter ego theory” of jurisdiction, has ruled that an Indian pharmaceutical company cannot be sued in New Jersey Superior Court despite its subsidiary’s physical presence in the state.
The court, in a Dec. 29 published ruling in FDASmart v. Dishman Pharmaceuticals and Chemicals, found “insufficient evidence presented to pierce the corporate veil and impute Dishman USA’s New Jersey contacts to” Dishman Pharmaceuticals, which is based in India.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
